ImmunoScience, Inc.
Contre-Vir™
![[Previous Page]](prevpage.gif){kind=small}
![[Next Page]](nextpage.gif){kind=small}
![[Up]](up.gif){kind=small}
![[Home Page]](homepage.gif){kind=small}
![[Mail]](mail.gif){kind=small}
![[Contents]](contents.gif){kind=small}
Contre-Vir™ Recombinant Virus Therapy and
Prevention for AIDS
During the
research in development of SALIVAX™ above, the company realized the mechanism
by which the HIV virus evades the body's immune system. By using recombinant
technology, a specific gene thought to be responsible for the virus's evasion
of the immune system was deleted from the virus's genetic code and a
"designer" HIV virus strain was created. After initial studies in
cell lines and SCID mice (an animal model), this virus vaccine (Contre-Vir™)
was introduced into two patients suffering from AIDS. Both of these patients
were close to a collapse of their immune systems and thus death. Two injections
were given about a month apart. Both these patients showed remarkable
improvement in that their CD4 ("Helper T Cells") increased in number
to normal levels, they started gaining weight, their opportunistic infections
disappeared and they felt subjectively better. An intermediate study performed
on eight patients yielded similar promising results. We are in the process of
organizing a multi-continent larger study with a double-blind randomized
statistical methodology and a considerably higher number of subjects. This
study has been slightly delayed due to the unpredictable nature of regulatory
approvals but is now slated to be underway in Asia, Africa and South America.
In this study, CD4 counts as well as viral load shall be measured.
During visits
by company scientists to Rio de Janeiro, Amsterdam, Brussels, Moscow, Nairobi
and Bangkok, the concept was received very favorably by leading researchers in
the respective countries and ImmunoScience has planned similar studies in near
future in collaboration with those scientists to prove that the various
mutations of the HIV virus do not affect the success obtained by the vaccine.
The concept can
also be applied to the treatment of certain cancers and certain other viral
infections. This concept and the recombinant virus are the subject of pending
US and International Patent applications and the name "Contre-Vir" is
the subject of a pending US Trademark application. An Australian patent has
already been granted and a US patent is expected to be granted soon.
View a Draft
Research Protocol outlining the scientific basis and methodology of Contre Vir™
|
|
|
SALIVAX™ |
|
|
Future... |
|
|
Our Products |
|
|
Home Page |
|
|
Send EMail to ImmunoScience, Inc. |
|
|
ImmunoScience, Inc. Contents |
Please note that ImmunoScience's products are the subject of many US and International patent applications. This document does not convey any rights to develop, manufacture, use or sell anything described herein.